Conference Coverage
Novel psoriasis biologic wows with jaw-dropping results
Key clinical point: Up to 66 months after receiving a single subcutaneous injection of a biologic agent that selectively blocks interleukin-23,...
Conference Coverage
EADV: Investigational biologic rocks psoriasis world
AT THE EADV CONGRESS
Recommended Reading
Related Articles
-
-
Conference Coverage
IL-23 inhibitor topped ustekinumab against psoriasis
Key clinical point: The interleukin-23 inhibitor BI 655066 outperformed ustekinumab and generated no concerning safety signals in a small phase II...
-
Conference Coverage
WCD: IL-23p19 inhibitors yield ‘promising’ psoriasis results